Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.64 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | GALR2 | O43603 | 1/20 | 0.36 |
| ▸ | GALR1 | P47211 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21573606 | 0.85 | ROCK2 (0.65) | ROCK2ROCK1CCNE1CDK2 | |
| SCHEMBL21573527 | 0.80 | ROCK2 (0.64) | ROCK2ROCK1SCN9AHSP90AA1HSP90AB1 | |
| SCHEMBL21573532 | 0.80 | ROCK2 (0.60) | ROCK2ROCK1CCNE1CDK2 | |
| SCHEMBL21573654 | 0.78 | ROCK2 (0.60) | ROCK2ROCK1SCN9ACCNE1CDK2 | |
| SCHEMBL17986445 | 0.78 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL21573609 | 0.76 | ROCK2 (0.62) | ROCK2ROCK1 | |
| SCHEMBL21573645 | 0.74 | ROCK2 (0.62) | ROCK2ROCK1 | |
| SCHEMBL24353315 | 0.73 | ROCK2 (0.53) | ROCK2ROCK1 | |
| SCHEMBL20783917 | 0.70 | ROCK2 (0.63) | ROCK2ROCK1 | |
| SCHEMBL21573537 | 0.70 | ROCK2 (0.35) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055301-B1 | (2-(5-ISOINDOLIN-2-YL)PYRIMIDIN-4-YL)-AMINE DERIVATIVES AS RHO KINASE INHIBITORS FOR TREATING AUTOIMMUNE DISEASES | KADMON CORP LLC (US) | 2019-11-20 | — | — | EP | disclosed |